Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant imatinib versus no further therapy after surgery for gastrointestinal stromal tumours
ACTRN12605000712606Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Time to Imatinib Failure. Started Oct 2008; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ACTRN12605000712606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000712606.